Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day by Collier, Mary E.. et al.
REVIEW ARTICLE
Extracellular vesicles, tissue factor, cancer and
thrombosis  discussion themes of the ISEV 2014
Educational Day
Chris Gardiner1*, Paul Harrison2, Mattias Belting3, Anita Bo¨ing4,
Elena Campello5, Bob S. Carter6, Mary E. Collier7, Frank Coumans4,8,
Camille Ettelaie9, Nick van Es10, Fred H. Hochberg6,11, Nigel Mackman12,
Robert C. Rennert6, Johannes Thaler13, Janusz Rak14 and Rienk Nieuwland4
1Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Level 3 Women’s Centre, John
Radcliffe Hospital, Oxford, UK; 2School of Immunity and Infection, University of Birmingham Medical School,
Birmingham, UK; 3Department of Oncology and Pathology, Clinical Sciences, Ska˚ne University Hospital,
Lund, Sweden; 4Department of Clinical Chemistry, Academic Medical Centre of the University of Amsterdam,
Amsterdam, The Netherlands; 5Department of Cardiologic, Thoracic and Vascular Sciences, University of
Padua Medical School, Padua, Italy; 6Division of Neurosurgery, University of California San Diego, La Jolla,
CA, USA; 7Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield
General Hospital, Leicester, UK; 8Department of Biomedical Engineering and Physics, Academic Medical
Centre of the University of Amsterdam, Amsterdam, The Netherlands; 9School of Biological, Biomedical and
Environmental Sciences, The University of Hull, Hull, UK; 10Department of Vascular Medicine, Academic
Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands; 11Department of Neurology
and Program in Neuroscience, Massachusetts General Hospital and Harvard Medical School, Boston, MA,
USA; 12Thrombosis and Hemostasis Program, Department of Medicine, UNC McAllister Heart Institute,
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 13Clinical Division of Haematology and
Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; 14Department of
Pediatrics, McGill University, Montreal Children’s Hospital Research Institute MUHC, Montreal, QC, Canada
Although the association between cancer and venous thromboembolism (VTE) has long been known, the
mechanisms are poorly understood. Circulating tissue factorbearing extracellular vesicles have been proposed
as a possible explanation for the increased risk of VTE observed in some types of cancer. The Interna-
tional Society for Extracellular Vesicles (ISEV) and International Society on Thrombosis and Haemostasis
(ISTH) held a joint Educational Day in April 2014 to discuss the latest developments in this field. This review
discusses the themes of that event and the ISEV 2014 meeting that followed.
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T
he association between cancer and venous throm-
bosis (venous thromboembolism, VTE) was first
recognized by Jean-Baptiste Bouillaud in 1823 (1).
VTE is a frequent complication in cancer patients and is
a leading cause of death. For example, pulmonary embolism
is responsible for 14% of deaths in cancer patients who die in
hospital (2). Different cancer types have different rates of
thrombosis, but the underlying mechanisms for the increased
risk of VTE are still incompletely understood (3). In the
early 1980s, tumour-derived and tissue factor (TF)-exposing
extracellular vesicles (EVs) were proposed as a possible
mechanism to explain the increased risk of VTE in cancer
patients (4,5). Cancer cells can express TF, which can be
released on EVs into the circulation. Although such procoa-
gulant TF-exposing EVs (TF-EVs) are associated with the
increased rates of VTE reported in cancer patients (6), this
mechanism remains controversial. Very few of the studies
reported in literature were performed in vivo. Furthermore,
isolation and measurement methods are not standardized
and comparable. Nevertheless, despite these limitations we
believe that there is already strong evidence that EVs play an
important role in tumour growth and development.
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It was against this backdrop that the International Soci-
ety for Extracellular Vesicles (ISEV) and the International
Society on Thrombosis and Haemostasis (ISTH) held their
first joint symposium on 29th April 2014 in Rotterdam, The
Netherlands, to discuss the latest developments in EVs, TF,
cancer and thrombosis. As with previous ISEV meetings,
cancer EV was a major topic during ISEV 2015 with 61 oral
and 28 poster cancer presentations. These covered EVs in the
tumour microenvironment, EVs in cancer metastasis and
EVs as tumour biomarkers. Excitingly, the role of EVs as
therapeutic agents or targets in cancer therapy is starting to
emerge as a strong theme.
Vesiculation in cancer
The emerging molecular complexity and cellular diversity
of human cancers challenge the traditional preoccupation
with only intracellular signalling pathways (7). It is
increasingly clear that exchange of biochemical informa-
tion with the environment may contribute also to malig-
nant growth (810). EVs may bridge the chromosomal
mutations (oncogenic), downstream epigenetic events, and
pathways of intercellular communication in cancer (11)
(Fig. 1). Indeed, oncogenic lesions, such as mutant epi-
dermal growth factor receptor (EGFR), HER2, and RAS,
impact cellular vesiculation processes, leading to release
and intercellular exchange of oncogenic proteins, tran-
scripts and DNA sequences (1215). Vesiculation is also
implicated as a removal mechanism for growth inhibitory
factors, tumour suppressors (1618), and non-coding
RNA (13,19,20), which will all promote tumour growth.
While the ability of cells to release EVs has been known
since the 1960s (21) and cancer cells have been studied in
this regard since the 1970s (22) and 1980s (23), the bio-
genetic pathways leading to formation of different EV
subsets in cancer remain obscure and controversial (24
27). So are the mechanisms of selective packaging of their
molecular cargo, properties, mechanisms of intercellular
trafficking (28,29) and their biological role in various
disease contexts (11). Hence there is a growing interest in
understanding the involvement of EVs in cancer progres-
sion (11,25,3033). Moreover, usage of EVs for drug
delivery (20,34) and vaccination (35) has attracted consider-
able interest, and intense efforts are underway to analyze
and remotely monitor cancer-specific molecular events by
taking advantage of their encapsulation in the cargo of EVs
circulating in blood and other biofluids (3640).
Horizontal gene transfer and vesiculation
Perhaps one of the most tantalizing aspects of cancer cell
vesiculation is its role in extracellular emission and horizontal
transfer of transforming oncogenes (11). Holmgren and
colleagues showed the ability of apoptotic vesicles (bodies)
to exchange functional oncogenic DNA between cells (41).
Vesicular transport of transposons and single-stranded DNA
amplicons containing MYC sequences was subsequently
described by Balaj et al. and postulated to be a mechanism
causing genomic instability in cells exposed to this material
(14). More recently, genomic DNA sequences containing
mutant H-Ras gene were found in the cargo of EVs produced
by viable cancer cells in vitro (15), and this finding was
confirmed in several other systems. EVs isolated from plasma
of cancer patients carry cell-free DNA (cfDNA) (42,43), and
material previously implicated in cellular transformation
(44). While it still remains unclear whether EVs containing
fragmented oncogenic DNA mediate horizontal gene trans-
fer (15), evidence exists with regards to oncogenic transcripts
(13) and proteins contributing to clonogenic growth, angio-
genesis, invasion and metastasis (12,32,4547). In addition,
horizontal transformation may also be a function of stimuli
unrelated to the passage of genetic cargo, but instead tumour-
related EVs can carry also other growth altering activities,
such as transglutaminase, with lasting effects on recipient
cells (48).
Other factors influencing vesiculation
Oncogenic transformation represents but one mechanism
implicated in cancer cell vesiculation. Indeed, the release of
EVs is also influenced by several other processes, such as
cellular adhesion, migration, differentiation, epithelial-to-
mesenchymal transition (EMT) and deregulation of stem-
ness (20,4954). Moreover, metabolic states and exposure
to hypoxia are reflected in the cargo of EVs produced by
cancer cells (55). These observations suggest that EV cargo
may not only serve as a source of information regarding
the genetic evolution of the malignant cell population, but
also reflect the functional and metabolic state of these cells.
It is also of interest that hypoxia may alter the biological
activity of tumour-related EVs and changes in cellular
energy metabolism could be expected to have analogous
effects (56).
Functions of cancer-derived EVs
Among many normal and abnormal cell populations that
may be exposed to cancer-derived EVs. Endothelial cells,
inflammatory cells and blood cells are especially interest-
ing in this regard, because these cells are immediately and
continually exposed to tumour EVs in the circulation, andFig. 1. The diverse roles of vesiculation in cancer.
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because these EVs may be responsible for the systemic
pathological impact of even localized forms of cancer. The
emerging understanding of the consequences of cancer-
derived EV exposure includes evidence for deregulation
of angiogenesis (45,5557), the inflammatory response,
metastasis (32,58) and cancer-related coagulopathy. In the
latter case, EVs constitute an attractive, albeit controver-
sial, mechanism of spreading the procoagulant state from
cancer cells into periphery leading to related morbidities,
such as VTE (3,30,31,5962). While EVs are often re-
garded as ‘‘carriers’’ of procoagulant TF activity in this
setting, it is also possible that cells that have taken up
tumour-related EVs may either expose or de novo express
TF still resulting in haemostatic perturbations (11).
Potential clinical relevance of cancer-derived EVs
The diversity and intrinsic heterogeneity of human cancers
may make the EV landscape associated with malignancy
exceedingly complex. However, therein exist opportunities
to exploit the vesiculation mechanisms in precision medi-
cine for tumour diagnosis, prognosis, prediction of, for
example, VTE or metastasis, monitoring of therapy, and
dedicated treatment, such as administration of autologous
EVs to increase the body’s immune response and to
eradicate the tumour.
With regard to prognosis of VTE, several EV-based
assays are now being studied to identify cancer patients at
high risk for developing VTE. To understand this devel-
opment, one of the goals of the ISEV 2014 Educational
Day was to discuss the related properties of TF, as the
primary cellular trigger of coagulation, followed by a
section on the currently available information on the
putative contribution of EV-associated TF to VTE.
EVs in coagulation
The importance of EVs or ‘‘microparticles’’ to blood co-
agulation has long been recognized. Indeed the first
described property of EVs was the ability to support
thrombin generation (TG) (21). The formation of the prin-
ciple complexes of the coagulation process, the intrinsic
and extrinsic tenases and prothrombinase, requires a
negatively charged phospholipid surface for the calcium-
dependent binding of the vitamin K-dependent clotting
proteins factors II (prothrombin), VII, IX and X (Fig. 2),
which increases their biological activity by several orders
of magnitude. During normal haemostasis, the negatively
charged surface is provided by aminophospholipid (APL)
externalization (predominantly phosphatidylserine) on
the platelet membrane and platelet-derived EVs. The in-
ability to externalize APL causes Scott syndrome, a rare
bleeding disorder (63). Following vascular damage, blood
is exposed to the subendothelium causing platelet activa-
tion and initiation of coagulation by perivascular TF.
Fig. 2. Tissue factor initiates coagulation by binding factor VIIa to form membrane bound complex which activates factor X. This
forms a complex with factor Va which activates prothrombin to thrombin. Thrombin activates factor XI which creates an amplification
loop through the factor IXa/VIIIa activation of factor X. The resulting burst of thrombin generation causes platelet activation and
conversion of insoluble fibrinogen to an insoluble thrombin clot.
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Only in pathological conditions, for example, sepsis, sickle
cell anaemia and cancer, is there a significant amount of
circulating TF, much of which is expressed by EVs.
Tissue factor
Background
TF (CD142) is a 263 amino acid integral transmembrane
protein. Full length TF (flTF) has 3 domains: an extracellular
domain (residues 1  219), a 23 amino acids transmembrane
domain, and a short 21 amino acids intracellular domain,
which is involved in signalling. The extracellular domain
of flTF binds coagulation factor VII or its activated form
(VIIa) with high affinity, thereby initiating blood coagulation
and mediating haemostasis (Fig. 2). TF also plays roles in
embryogenesis, angiogenesis, and inflammation (64). There
is also a second form of TF known, alternatively spliced
TF (asTF). This is a soluble version that lacks the transmem-
brane domain. Whereas soluble asTF has little or no pro-
coagulant activity, asTF can stimulate angiogenesis indepen-
dently of FVIIa and when bound to integrins on the cell
surface acquires procoagulant activity (65).
TF is constitutively expressed by extravascular cells,
such as adventitial fibroblasts, thereby providing a haemo-
static envelope that can initiate haemostasis upon vessel
wall damage. In fact, under normal conditions all compo-
nents required for coagulation, such as coagulation factors
and calcium ions, are sufficiently present within the blood,
but coagulant TF, the initiator of coagulation, and is pre-
sent only outside the blood vessel. Upon vascular damage,
blood will contact the extravascular TF and coagulation
will be initiated. Only under exceptional pathological
conditions, can circulating cells, such as monocytes and
cells lining the vessel wall (endothelial cells) express and
produce coagulant TF. TF has also been detected in other
types of circulating cells, such as platelets, but this may be
due to binding to TF-positive EVs (66).
Although the molecular mechanisms regulating the
coagulant activity of TF are still incompletely understood,
this activity is increased in damaged cells due to the pres-
ence of the negatively charged phospholipid phosphati-
dylserine, and by thiol-disulphide bond modifications of
the TF molecule. This concept of circulating blood-borne
‘‘thrombotic’’ TF on EVs (TF-EVs) is therefore of great
interest, not only given their potential as biomarkers of
major diseases, such as cancer, but also on their putative
contribution to the development of thrombosis.
TF-exposing vesicles and coagulation activation in
animal studies
Many lines of evidence suggest that TF-EVs are involved
in coagulation activation in vivo, either directly or indi-
rectly by adhesion to the damaged vessel wall.
Animal studies have shown that tumour-derived EVs are
released from a variety of tumours in vivo, and that these
EVs expose procoagulant TF as demonstrated in vitro. In the
circulation of mice bearing an orthotopic tumour derived
from a human pancreatic cancer cell line, the human TF
coagulant activity of the tumour-derived EVs was paralleled
by in vivo coagulation activation. Moreover, plasma from
the tumour-bearing mice increased TG in vitro in a human
TF-dependent manner, and the inhibition of human TF
reduced thrombinantithrombin (TAT) levels in vivo, an
indication of coagulation system activation (6,67).
In addition, tumour-derived EVs enhance the devel-
opment of thrombosis in mice in vivo. Thomas and
colleagues found that cancer cellderived EVs, after
infusion into the circulation of a living mouse, accumu-
lated at the site of vessel injury by binding to activated
platelets, suggesting that tumour-derived EVs participate
in thrombus formation in vivo (68).
Retrospective studies on TF-exposing vesicles,
coagulation activation, and venous thrombosis in
cancer patients: cause or consequence?
Several retrospective studies have analyzed the levels of
circulating TF-EVs in patients with cancer. In general,
elevated levels of circulating TF-EVs have been reported
compared to healthy controls, and these increased levels
are associated with in vivo coagulation activation, for
example, in colorectal cancer patients (69) and in patients
with early prostate cancer (70). However, one cannot
conclude from these studies that high levels of circulating
TF-EVs in blood of cancer patients are a causal factor for
the development of VTE.
Tesselaar and colleagues were the first to report that the
TF-EV coagulant activity is higher in pancreatic and
metastatic breast cancer patients who presented with VTE
compared to cancer patients without VTE (71). This find-
ing was confirmed in later case-control studies (72,73).
Similarly, Zwicker and colleagues (74) observed TF-EVs
in plasma of 60% of the cancer patients with VTE,
compared with 27% of patients with cancer without
VTE. Moreover, in 3 patients undergoing pancreatectomy,
the TF-EV level was markedly reduced after surgery.
In a 1-year follow-up, 25% (4 out of 16) patients with
detectable TF-EV levels developed VTE, compared with
0% (0 out of 44) in patients without detectable TF-EVs, a
finding confirmed recently by Campello et al. (75). One
has to bear in mind, however, that these studies do not
provide an answer to the question whether the increased
presence of coagulant TF-EVs is either cause or conse-
quence of cancer-associated VTE.
Prospective studies on TF-exposing vesicles,
coagulation activation, and venous thrombosis in
cancer patients
The most extensive prospective study measured TF-EV
activity in plasma samples from the Vienna Cancer and
Thrombosis Study (CATS) (76). A total of 348 patients
suffering from pancreatic, gastric, colorectal or brain
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cancer, had a 2-year follow-up for the occurrence of
symptomatic VTE. Patients with pancreatic and gastric
cancer expressed higher levels of coagulant TF-EV activity
in comparison to patients with brain and colorectal
cancer. Moreover, patients with pancreatic cancer demon-
strated borderline significance for an association between
TF-EV activity and development of VTE, whereas this
association was not found for 3 other tumour types. This is
in line with findings of a later study which demonstrated
an association between elevated plasma TF-EV activity
and development of VTE in patients with newly diagnosed
cancer of pancreaticobiliary origin (77). Recently, the
interim results of a prospective study which evaluated
the predictive value of TF-EV activity for VTE in 88
patients with pancreatic cancer were reported (78).
Patients with a high TF-EV activity at baseline were 6
times more likely to develop deep vein thrombosis (DVT)
or pulmonary embolism (PE) during 6 months follow-up
compared to patients with low EV-TF activity, although
statistical significance was not reached (HR 6.0; 95% CI
0.7448.99). Nevertheless, taken together with the find-
ings of other studies, these results support a role for TF-
EVactivity as a predictive biomarker for cancer-associated
VTE in pancreatic cancer patients.
Also in patients with glioblastoma multiforme (GBM),
levels of circulating TF-EVs are increased compared to
healthy controls (60). Furthermore, patients who developed
VTE during 7 months follow-up had significantly higher
levels of TF-EVs at baseline than the non-VTE patients.
This study was expanded in order to confirm the results
(unpublished data). Twenty-five GBM patients and 20
patients with meningioma, a prothrombotic benign neo-
plasm, were included and followed for up to 7 months.
Both these brain neoplasms had higher levels of TF-EVs
compared to healthy subjects, as shown in Fig. 3, Panel a.
Seven glioma patients developed VTE during follow-up,
and these patients presented with significantly higher
levels of TF-EVs at baseline and 1 month after surgery. In
contrast, 2 meningioma patients developed VTE but they
did not present with higher levels of TF-EVs compared
with patients without VTE. A possible explanation is that
circulating TF-EVs in patients with GBM are more
procoagulant than those TF-EVs in patients with menin-
gioma. However, since only a minority of TF-EVs in
GBM patients also stained for GFAP (10%) (Fig. 3, Panel
b), a marker for glial cells, the true cellular origin of
coagulant EV-associated TF in blood still remains to be
determined.
The main question obviously is, whether coagulant TF-
EV activity can be used to predict who will develop VTE,
so that prevention of VTE becomes a realistic option. In a
recent, small phase II study (the Microtec study) 66
patients with advanced cancer (30 pancreatic, 21 non-small
cell lung and 15 colorectal) were assigned into 1 of 2 groups
Fig. 3. (a) TF-bearing EVs in glioma and meningioma patients and in healthy controls. (b) Origin of TF-bearing EVs in glioma patients
and controls.
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on the basis of the number of circulating TF-EV: low TF-
EVs (53.5104/ml) or high TF-EVs (3.5104/mL) as
measured with impedance-based flow cytometry. The low
TF-EV patients were followed without treatment. The
high TF-EV patients were randomized to either enox-
aparin or observation without treatment. The untreated
high TF-EV patients had a higher 2-month cumulative
incidence of mostly asymptomatic venous thrombosis
compared with low TF-EV patients, 27% versus 7%,
respectively. High TF-EV patients randomized to enox-
aparin had a low cumulative incidence of venous throm-
bosis (6%). Thus, it may be feasible to use the number of
circulating TF-EVs to identify patients at high risk for
developing VTE, and thus patients eligible for prophy-
lactic anticoagulant therapy (79).
Is there a role for EVs exposing coagulant
TF in cancer-related thrombosis?
As summarized in the previous sections, experimental
and cross-sectional clinical studies provide evidence that
TF-EVs in cancer patients represent a coagulant EV
subpopulation that may play a role in the prothrombotic
state found in different malignancies (3). At present,
however, results from prospective studies that investigated
the potential of TF-EV coagulant activity as a biomarker
for prediction of future VTE in cancer patients are
inconsistent. It needs to be kept in mind that ambiguous
results can result from inclusion of different types and
stages of cancer and the presence of only limited data from
large prospective studies, but also methodological dis-
crepancies and a lack of standardization. For instance, the
sensitivity of conventional flow cytometry is too low to
detect the majority of TF-EVs which hampers interpreta-
tion of the results. Hence, functional assays are in general
preferred to measure TF-EVs, but it is yet unknown which
is the best assay for measuring the coagulant activity of
the TF-EV population. Also pre-analytical variables, such
as blood withdrawal, EV isolation, and EV preparation
are not consistent across the studies. However, despite
these differences, evidence primarily in patients with pan-
creatic cancer indicates that TF-bearing EVs might play
an important role in the pathogenesis of VTE.
Unanswered questions
a. Although cancer chemotherapy is associated with in-
creased risk of VTE (80,81), Tesselaar found no ele-
vated plasma TF-EV activity in patients treated with
chemotherapy (73). More recently, also no increase in
TF-EV activity was observed in response to che-
motherapy in breast cancer patients (82), or in GBM
patients (60). These findings suggest that mechanisms
other than increased levels of circulating and coagu-
lant TF-EVs are responsible for thrombosis during
in response to chemotherapy, for example, increased
neutrophil extracellular trap formation or increased
apoptosis and/or necrosis. Again, most studies are
small and effects of chemotherapy may differ be-
tween various types of cancer. Clearly, larger and
more mechanistic studies are necessary to address
this question.
b. Although an association between the level of TF-EV
release and thrombosis has been established for some
types of cancer, causality has not yet been firmly esta-
blished. The results of future prospective clinical trials
should aim to identify any causative relationship.
c. Another issue is the optimum timing of sampling.
TF-EV coagulant activity progressively increased in
the months prior to the development of thrombosis,
but baseline levels may be similar to those patients who
did not develop thrombosis (3). Thus, a single base-
line sample may not be sufficient to predict future
thrombotic events. Furthermore, basal TF-EV deter-
mination was found to be correlated with VTE in
studies over a 6-month period but only weakly in
studies with a 2-year follow-up (3).
Mechanisms for the selective incorporation
of TF into EV
One important aspect in the formation of TF-containing
EVs involves understanding the mechanisms by which TF
is incorporated into EVs.
Role of serine phosphorylation
The induction and termination of the incorporation of
TF into EVs seems regulated by phosphorylation of
2 serine residues within the cytoplasmic domain of TF
(83). The phosphorylation of Ser253 is involved in the
incorporation and release of TF within EVs (Fig. 4a).
Upon cellular activation, protein kinase C-a phosphorylates
Ser253 (84,85), resulting in the interaction of phosphory-
lated TF with the cytoskeletal protein filamin-A (86,87)
(Fig. 4b). The termination of TF incorporation in EVs
may be regulated by phosphorylation of Ser258 (83,88)
(Fig. 4a). This phosphorylation occurs only after phospho-
rylation of Ser253 (83,84) and is mediated by p38a (88).
Interestingly, the incorporation of TF into EVs seems to
occur via different mechanisms to that of the formation of
the EVs themselves. Firstly, inhibition of the incorporation
of TF into EVs does not interfere with the release of EVs
(83,87). Secondly, preliminary studies suggest the involve-
ment of caspases but not calpains in the incorporation of
TF into EVs (Collier et al., unpublished data), which both
are thought to contribute to the release of EVs (89).
In conclusion, the regulation of the release of TF into
EVs is mediated through mechanisms regulated by phos-
phorylation of the cytoplasmic domain of TF and may
involve the cytoskeletal protein filamin-A. The phosphory-
lation of TF in turn also induces feedback-signalling
mechanisms which promote cell proliferation or apopto-
sis, depending on the level of TF within the cell.
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These mechanisms may constitute part of the process
used by cells to gauge the level of surrounding injury and
trauma, and contribute to how cells determine the
appropriate response to injury (88,9098).
Role of the microenvironment
TF can be present in a coagulant or a non-coagulant form.
The underlying mechanisms to switch between both forms,
however, are still unclear but may involve (a) dimerization
(99), (b) exposure of anionic phospholipids (100), (c)
oxidation and reduction of the disulphide bonds (Cys186
Cys209) of TF (101), and/or (d) the association with lipid
rafts (102).
The role of rafts has remained especially obscure, par-
ticularly for TF present in plasma membranes, in other
words cell-exposed TF. In previous studies, the associa-
tion between TF and lipid rafts, also known as detergent-
resistant membranes (DRMs), was determined in whole
cell lysates. Because in whole cell lysates most TF origina-
tes from intracellular membranes (103), the role of DRMs
in regulation of TF coagulant activity has remained
controversial (103105). Therefore, the association of TF
with DRMs was studied in purified plasma membranes
and in EVs.
Plasma membranes of various human TF producing
cells and cell lines contain 2 different types of DRMs
based on density, DMR-H with high density and DRM-L
with low density. DRM-H contains the bulk of TF,
but lacks any detectable coagulant activity. In contrast,
DRM-L contains only minute amounts of TF, but this
TF initiates coagulation. So, different forms of coagu-
lant and non-coagulant TF seem to co-exist in plasma
membranes. The lack of coagulant activity was not due
to the presence of the endogenous plasma inhibitor of
TF, tissue factor pathway inhibitor (TFPI). In contrast,
the regulator of oxidation and reduction of disulphide
bonds, protein disulphide isomerase (PDI), was present
in DRM-H, suggesting that PDI may be involved in
keeping TF in a dormant, non-coagulant form. Similarly
to plasma membranes, vesicles from smooth muscle cells
and human saliva, both known to contain coagulant TF
(106), also contain DRM-H and DRM-L. Again, the
non-coagulant form of TF and PDI were associated with
DRM-H, whereas the coagulant form was associated
with DRM-L.
With this knowledge, a model for the release of TF-
EVs can be proposed, shown in Fig. 5, which may help to
explain the observed discrepancy between the presence
of detectable levels of TF-EVs and the concurrent lack of
TF coagulant activity, both in mouse models (67) and
cancer patients (107). With our model, we hypothesize
the existence of TF-EVs originating from different mem-
brane compartments. In this model, the non-coagulant
TF-EVs are exclusively released from the DRM-H com-
partments of the plasma membrane (option 1, Fig. 5),
whereas the coagulant TF-EVs are released from DRM-L
compartments of the plasma membrane only (option 2,
Fig. 5). Although not shown in Fig. 5 for clarity, it seems
likely that hybrid vesicles may occur which contain both
forms of TF.
TF in tumour angiogenesis
Cancer cells thrive in the tumour microenvironment.
Several stress-related phenomena of this microenviron-
ment such as hypoxia, acidosis, starvation, and coagula-
tion (108,109), are major drivers of tumour development
and aggressiveness, and thus select for tumour cells that
successfully adapt to microenvironmental stress. This
adaptive response of cancer cells is strongly associated
with resistance to oncological treatment. However, such
mechanisms also represent potential Achilles’ heels of
the cancer cell machinery and thus may offer alternative
treatment targets of cancer (110).
Fig. 4. (a) The phosphorylation of Ser253 within the cytoplasmic domain acts to initiate the incorporation and release of TF within
EVs. (b) The interaction between TF and filamin-A is required for the active incorporation of TF into EVs.
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It was previously shown that the coagulant TFFVIIa
complex promotes retinal angiogenesis through protease-
activated receptor-2 (PAR-2) (91). For example, hypoxic
cancer cells release EVs exposing the TFFVIIa complex
that induce PAR-2-mediated angiogenesis (55) (Fig. 6).
In addition, hypoxia also affects the sorting, of mRNAs
and proteins involved in tumour development, to EVs
from glioma cells and these EVs are present in plasma
of glioma patients (56). It may be concluded that EVs
represent novel players in hypoxia-dependent cross talk
between malignant cells and stromal endothelial cells
during tumour formation. Further, the EV molecular com-
position may reflect the oxygenation status and aggres-
siveness of malignant tumours.
Techniques for analyzing EVs
Measurement of EVs in suspension
EVs are heterogeneous in origin, size and function (111).
To determine their origin and number, measurements
of size, concentration and antigens at the level of single
EV is required. At this time, however, only several im-
perfect EV detection technologies are available. Here,
only methods for the detection of EVs in suspension will
be discussed.
Flow cytometry is the most applied technique for EV
detection. A sensitive system can detect the scatter and
fluorescence phenotype of more than 100,000 EVs per
minute, with fluorescence sensitivity of 50 antigens on a
single EV. Due to their small size, low refractive index
and low number of antigens, the fluorescence and scatter
signals from EVs are difficult to distinguish from the
noise, causing the smallest EV to pass undetected. Due to
the large number of small (112), co-incidence or swarm
detection may occur (113). Due to differences in refrac-
tive index, gating using polystyrene beads does not result
in gating of the same size for EVs.
In a typical flow cytometer, one of the detector
channels is used for triggering. If the signal in the trigger
channel exceeds a threshold level, any potential signals in
all the detection channels are also then recorded. Because
the fluorescence sensitivity of a typical flow cytometer is
higher than the scatter sensitivity, triggering on fluores-
cence may result in detection of smaller EVs. Fluores-
cence triggering will only detect fluorescent EVs, which
still means either a subset of EVs is detected or a complex
protocol is needed to label all EVs (114). To date, a
suitable pan-EV marker has not been identified.
In resistive pulse sensing, a single EV is pushed through
a pore. An electrical circuit measures the resistance of the
pore. When an EV moves through the pore, the resistance
increases, and this increase is proportional to the volume
of the EV (115). To date, the major limitation of resistive
pulse sensing is that it lacks the possibility to determine
antigen expression on EVs.
Nanoparticle tracking analysis relates the rate of
Brownian motion to EV size. This relation requires know-
ledge of the medium viscosity and temperature. The
refractive index of EVs does not affect the size that is
measured, but does affect the minimum detectable size.
Although nanoparticle tracking analysis can measure
fluorescence, the sensitivity needs to be improved (112).
The system requires careful calibration (116), and deter-
mined size and concentration have limited accuracy and
precision (115).
In cryo-electron microscopy (EM), the sample is label-
led with the immune-gold method, and snap frozen before
analysis (117). This approach has several major advan-
tages. The minimum detectable size is in the order of nano-
metres, and this method allows immune-phenotyping of
Fig. 5. Model for the release of TF-exposing vesicles. TF-exposing
vesicles originating from different membrane compartments.
Fig. 6. TF-dependent coagulation activation is of relevance for
metastasis, tumour growth, and angiogenesis through several
distinct mechanisms, including the activation of thrombin further
resulting in the generation of a fibrin network, and platelet
activation. These end stages of coagulation can contribute to
tumour progression and metastasis by, for example, protection
of circulating cancer cells from immune cell attack. In addition,
TF and associated coagulation proteases up-stream of thrombin
can cleave and activate protease-activated receptors (PARs) to
induce pro-migratory and survival signalling in cancer cells.
Endothelial cells, however, are normally devoid in TF. At hypoxic
conditions, cancer cells may release TF/FVIIa-bearing EVs that
in a paracrine manner trigger an angiogenic response through
activation of PAR-2 in endothelial cells. Further, it may be
hypothesized that systemic release of TF-EVs from hypoxic
tumour regions contributes to the hypercoagulable state of cancer
patients.
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all EVs. The major disadvantages, however, are that
concentration determination is in its infancy, and that
the time needed for a measurement precludes clinical
application.
In summary, at this time no technique capable of measur-
ing size, concentration and antigen expression of single
EV exists. However, each of the techniques discussed is
evolving rapidly, and we expect suitable detection tech-
niques to become available in the near future.
Measuring EV-associated TF
Measurement methodologies for (full length) TF can
be classified into antigenic and functional  mostly
coagulant  assays. At present, there is a lack of stand-
ardization in the measurement of TF-EVs. Therefore,
measuring EV-associated TF antigen or TF coagulant
activity presents even more problems than one would nor-
mally encounter (see Table I). In general, the TF antigen-
based assays lack the sensitivity necessary to detect the
low levels of coagulant TF-EVs in blood (118).
EV-TF coagulant activity
Despite limitations, however, it is possible to measure
a true TF-EV coagulant activity by using appropriate
positive controls such as monocyte-EV-TF and specific
inhibitory antibodies against TF or FVIIa. One approach
to detect TF-EV coagulant activity is to isolate EVs by
ultracentrifugation, which are washed and then incubated
with purified human coagulation factors to generate
coagulation factor Xa, which activity is measured using
a chromogenic substrate. Alternatively, the TF-EV coa-
gulant activity can also be measured directly in the
plasma after recalcification. Also several commercial
assays are available to measure TF-EV coagulant acti-
vity, but the sensitivity of such assays is relatively low
(118). So far, measuring TF-EV coagulant activities have
been insufficiently compared or standardized between
laboratories.
EV-TF antigen detection
The most popular method to measure TF-EVs is flow
cytometry. Measurement of cell-associated TF has crea-
ted controversy in the past, so one can appreciate that
these difficulties are multiplied when measuring EVs.
Again the use of appropriate controls is a prerequisite.
Recently, commercially available clones of TF antibodies
were compared (119). This study revealed a great deal of
variability (up to 2 or 3 orders of magnitude) between
clones in non-specific binding, avidity and the ability to
inhibit TF activity. In addition to selecting the appro-
priate antibody clone, the need for target-specific titration
of the antibodies and selection of the brightest fluor-
ophores were also identified as critical factors in achiev-
ing adequate sensitivity and specificity when measuring
TF by flow cytometry.
In summary, measurement of TF-EVs is still in its
infancy and requires larger and comparative studies to
pave the road towards more standardized measurements
and inter-laboratory acceptance of applied methods and
obtained results.
High-grade gliomas as a model disease
for EV studies
Primary high-grade gliomas, particularly glioblastomas
(GBM), arise from progenitor and supporting glial cells
in the brain. Patients experience poor survival despite
advances in surgical and chemotherapeutic approaches
(120). A major contribution to mortality and recurrent
hospitalization emerges from a high risk of VTE. These
complications profoundly impact the cost of GBM treat-
ment. Our limited understanding of the pathophysiology
of GBM-related hypercoagulability, combined with the
haemorrhage risk of anticoagulation therapy, has pre-
vented the establishment of a consensus on the role of
anticoagulation in patients with GBM. This population
represents an appealing model upon which to base the
validation of novel markers of coagulation risk and to
Table I. Issues with measurement of MV-associated TF.
Pre-analytical variables  cell-free plasma, anticoagulant, g-values for centrifugation, discard tube in blood draw, freeze thawing
TF activity can be increased by post-translational modification and decreased by its inhibitor tissue factor pathway inhibitor
Higher concentrations of Factor VIIa can activate FX in a TF-independent manner in the presence of phospholipids
Binding of Factor VII/VIIa to TF blocks access of some anti-TF antibodies
The contact pathway may activate coagulation in some clotting-based assays with low TF as initiator. This pathway can be inhibited
Presence of antibody microaggregates causing false positive signals in flow cytometry studies
Detection limit of most flow cytometers above the size of small TF-positive vesicles
Few studies simultaneously compare more than one assay
No accepted international standard
No gold standard assay  the MP TF activity assay is the best available assay
Positive (plasma from whole blood treated with LPS) and Negative Controls (use of inhibitory antibodies are important to confirm that the
procoagulant activity measured is due to TF)
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design studies to identify patients most likely to benefit
from prophylactic and therapeutic anticoagulation.
Identification of clinically relevant GBM subtypes
Molecular subtyping of GBM has increased our under-
standing of these tumours and disclosed heterogeneity
that demands individualized molecularly-targeted treat-
ment approaches (120). Specifically, integrated genomic
analysis has identified 4 clinically relevant GBM sub-
types, which differ in clinical prognosis, response to
therapy, survival, and the risk of developing VTE (120).
Venous thromboembolism in GBM: incidence,
cost and relationship to molecular subtype
The incidence of VTE is of particular concern in patients
with brain tumours (121,122). In GBM, VTE affects be-
tween 3 and 20% of patients in the post-operative period
(122), with a cumulative lifetime risk of up to 32% (123).
While the cost of treating VTE in patients with GBM has
not been specifically examined, the estimated annual
provider payments associated with a DVT diagnosis are
$7,000 to $10,000 (124). Similarly, a PE diagnosis is
estimated to cost between $13,000 and $16,000 (124).
Re-admissions, a particularly relevant concern in GBM
patients with VTEs given their persistently increased
thrombotic risk and the unclear long-term anticoagula-
tion guidelines for this group, can occur in up to 14.3% of
patients with VTE and are associated with similar or
higher treatment costs (124).
Mirroring the survival heterogeneity of GBMs, the risk
of VTE is variable across high-grade gliomas (125). There
is also indirect evidence that GBM molecular subtype
can affect VTE risk (52,126), making this GBM classi-
fication scheme appealing as a predictor of thrombotic
risk. Current GBM subtyping nonetheless requires pri-
mary tissue samples for genetic analysis, limiting its utility
to the post-operative setting. Less invasive biomarkers,
such as diagnostic biofluid analyses of tumour-specific
exosome amplifications and mutations of GBM subtypes
are needed in order to fully characterize their impact on
thrombotic risk.
Pathophysiology of VTE in GBM
Understanding the pathophysiology of VTE in GBM
is critical to risk stratification and can provide insight
into potential GBM subtype biomarkers. In addition to
demographic thrombotic risk factors, there are both
treatment- and glioma-associated mechanisms that can
affect patient risk (122). Gliomas themselves can directly
affect VTE risk through the upregulation or ectopic expres-
sion of procoagulant molecules, including TF (122,127).
Underscoring this direct causal relationship, the extent
of tumour resection demonstrates an inverse thrombo-
tic risk correlation. Expression of glioma-specific pro-
coagulants can also be stratified based on GBM molecular
profile (126), highlighting the potential utility of GBM
subtype defining biomarkers as prospective indicators of
VTE risk.
Thrombotic management and risk avoidance
in GBM
Effective management and prophylaxis of VTE in patients
with GBM involves balancing the risk of VTE with the
risk of intracranial bleeding due to anticoagulation.
Given the risks of VTE in GBM, prophylactic anti-
coagulation is appealing but a large multicentre, phase
III, placebo-controlled trial assessing prophylactic antic-
oagulation was terminated early by the sponsor (128).
Therefore, the safety and efficacy of this approach remains
unknown. Biomarkers identifying those patients at in-
creased risk for VTE would significantly aid clinical deci-
sion making in this population.
EVs as biomarkers of GBM thrombotic risk
GBM-secreted EVs are appealing diagnostic biomarkers.
GBM-specific proteins or genetic material, such as the
mutated epidermal growth factor receptor EGFRvIII and
enzymes IDH1/IDH2), are detectable in both the plasma
and CSF at levels significantly above healthy controls
(129). Because the levels of these markers decrease with
surgical resection (129), they are appealing as markers for
tumour recurrence. EVs have also shown prognostic
utility in GBM, as patients with higher levels of GBM-
derived EVs are more likely to fail standard treatment
protocols (129).
EVs are potentially ideal biomarkers of both GBM
molecular subtype and thrombotic risk, especially given
the likely association of these 2 phenomena (126). Thus,
overexpression of EGFRvIII correlated with classical type
of GBM, has been found to drive prothrombotic TF
production and is likely responsible for the increased
coagulant profile associated with this subtype (120,126).
Further, cancer cellderived TF-EVs induce procoagu-
lant activity in the endothelium (52). These data suggest a
causative relationship between the classical GBM onco-
genic pathway and increased thrombotic risk, with TF-
EVs serving as a detectable intermediary. Validation of
this relationship in the clinical setting demands further
exploration, as does the identification of analogous bio-
markers for the remaining GBM subtypes.
The recent clinical trial exploring other biomarkers
of cancer-related thrombotic risk provides a roadmap
for this work (121). Similar trials investigating the utility
of exosomes as GBM biomarkers are needed to: (a)
prospectively correlate GBM-specific EVs with molecular
subtype and risk of VTE, and (b) test the role of pre-
ventative anticoagulation in those GBM subtypes with
increased thrombotic risk. TF-EVs, identified by either
analysis or functional assay, are suited for trials assessing
their predictive value as markers for both the classical
GBM subtype and for increased thrombotic risk. Com-
bined with identification and testing of additional GBM
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subtypespecific exosomes, this approach could facilitate
individualization of GBM treatment plans based on
tumour-specific risk profiles.
Taken together, a role for EVs in complex processes
such as cellular transformation, tumour growth and devel-
opment, and the risk of VTE is emerging. Although there
is a growing clinical interest in the application of EVs as
(a) biomarkers for diagnosis and prognosis, (b) thera-
peutic application, (c) usefulness to monitor therapeutic
efficacy, (d) patient risk stratification to enable persona-
lized medicine, more and much larger studies will be
essential to firmly establish the clinical relevance of EVs.
Nevertheless, we hope that the present review will in-
crease the understanding of EV investigators from differ-
ent fields.
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